Category Archives: Deals

Pfizer–AstraZeneca: Implications for the Future of International Pharma

By Peter O’ Donnell. The Pfizer-AstraZeneca courtship raises many fascinating questions about the future shape of the international pharmaceutical industry, but it is also revealing some remarkable displays of parochialism. Even the olympian Financial Times has been displaying some nationalistic sympathies that sit oddly with its customary laissez-faire liberalism. A recent editorial seemed to argue strongly for some form […]
Also posted in Europe, Global, Guest Blog, Op-Ed, Safety | Tagged , , | 2 Comments

The United Kingdom: Rx for America's Pharma Tax Blues?

by Tom Norton The dizzying flurry of press releases from both Pfizer Inc. and AstraZeneca over a possible PFE acquisition of AZN have Rx experts on both sides of the Atlantic buzzing… From the US side, the most frequent thing that I have heard over the last 48 hours is, “You have got to be […]
Also posted in Corporate Responsibility, Europe, FDA, Global, Guest Blog, leadership, Legal, People, Strategy | Tagged , , , , , , , , | 1 Comment

Pfizer’s AZ Bid Draws Mixed UK Reaction

The confirmation of Pfizer’s bid for an outright acquisition of AstraZeneca has drawn mixed reactions from the UK. Linda McCulloch of Britain’s biggest union, Unite, said the bid is “very worrying for the UK workforce”, adding that it is “absolutely crucial” that there should be “guarantees of no jobs losses and for the protection on the UK’s […]
Also posted in Europe, Global, Supply Chain | Tagged , , , | Leave a comment

Big Pharma’s Big Tuesday: A New Age of Megamerger?

What’s the opposite of Black Tuesday? White Tuesday? Bright Tuesday? Because Tuesday the stock market was buzzing following the news that Novartis is to acquire GSK’s cancer drugs business, while selling its vaccines division to GSK. With the speculation of a $100bn Pfizer bid for AstraZeneca and Valeant Pharmaceuticals added in, prices went soaring. As of […]
Also posted in Europe, Global, Strategy | Tagged , , , , , | Leave a comment

CRO M&As Show No Sign of Slowing Down

By Lisa Henderson. With all of the activity in CRO M&As the past three years, it’s slightly amazing that it continues — and that analysts don’t see it slowing down. In fact, investment analysts speaking to the Partnerships in Clinical Trials event this month believe that from a Wall Street perspective, the publicly-traded CROs are […]
Also posted in Guest Blog, Strategy | Tagged , , , , | Leave a comment
  • Categories

  • Meta